{
    "APL": {
        "First relapse (morphologic or molecular)\u2070": {
            "Early relapse (<6 mo) after ATRA and arsenic trioxide (no anthracycline)": {
                "Therapy for relapse": [
                    "Anthracycline-based regimen as per APL-3\u1d56,\u146b",
                    "Gemtuzumab ozogamicin\u00b9\u00b2"
                ]
            },
            "No prior exposure to arsenic trioxide OR early relapse (<6 mo) after ATRA + anthracycline-containing regimen\u00b9\u00b9": {
                "Therapy for relapse": [
                    "Arsenic trioxide \u00b1 ATRA\u00b9\u00b9 \u00b1 gemtuzumab ozogamicin\u1d56,\u146b"
                ]
            },
            "Late relapse (\u22656 mo) after arsenic trioxide-containing regimen": {
                "Therapy for relapse": [
                    "Arsenic trioxide \u00b1 ATRA \u00b1 (anthracycline or gemtuzumab ozogamicin)\u1d56,\u146b,\u02b3"
                ]
            }
        },
        "Second remission (morphologic)": {
            "Additional therapy": {
                "Consider CNS prophylaxis": "IT chemotherapy (methotrexate or cytarabine)",
                "PCR result (by BM)": {
                    "PCR negative": {
                        "Transplant candidate": "Autologous HCT\u02e2",
                        "Not transplant candidate": "Arsenic trioxide consolidation (total of 6 cycles)"
                    },
                    "PCR positive": {
                        "Transplant candidate": "Matched sibling or alternative donor HCT\u02e2,\u00b9\u00b9",
                        "Not transplant candidate": "Clinical trial"
                    }
                }
            }
        },
        "No remission": {
            "Next steps": [
                "Clinical trial",
                "Matched sibling or alternative donor HCT\u02e2"
            ]
        }
    }
}